Article information
Full text is only aviable in PDF
References
[1.]
M. Descalzo, D. Montero, A. Erra, S. Marsal, M. Fernandez Castro, J. Mulero, et al.
Spanish registry for adverse events of biological therapy in rheumatic diseases (BIOBADASER): State report, January 26th, 2006.
Reumatol Clin, 3 (2007), pp. 4-20
[2.]
M.U. Rahman, I. Strusberg, P. Geusens, A. Berman, D. Yocum, D. Baker, et al.
Double-blinded infliximab dose escalation in patients with rheumatoid arthritis.
Ann Rheum Dis, 66 (2007), pp. 1233-1238
[3.]
T. Bongartz, A.J. Sutton, M.J. Sweeting, I. Buchan, E.L. Matteson, V. Montori.
Anti-TNF antibody therapy in rheumatoid arthritis and the risk of se-rious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.
JAMA, 295 (2006), pp. 2275-2285
[4.]
S. Schwartzman, G.J.J. Morgan.
Does route of administration affect the outcome of TNF antagonist therapy?.
Arthritis Res Ther, 6 (2004), pp. S19-S23
[5.]
Sociedad Española de Reumatología. Guía de Práctica Clínica para el Manejo de la Artritis Reumatoide en España. 2007 [cited March 3, 2008]. Available at: www.ser.es Carmona L. Cambios entre anti-TNF, ¿están siempre justificados?
[6.]
L. Carmona, A. Ortiz, M.A. Abad.
How good is to switch between biologics? A systematic review of the literature.
Acta Reumatol Port, 32 (2007), pp. 113-128
[7.]
K.M. Kamal, S.S. Madhavan, J.A. Hornsby, L.A. Miller, J. Kavookjian, V. Scott.
Use of tumor necrosis factor inhibitors in rheumatoid arthritis: a national survey of practicing United States rheumatologists.
Jt Bone Spine, 73 (2006), pp. 718-724
[8.]
V. Rodriguez-Valverde, R. Caliz Caliz, J. Alvaro-Gracia Alvaro, J. Marenco de la Fuente, J. Mulero Mendoza, J. Tornero Molina, et al.
Update of the Consensus of the Spanish Society of Rheumatology on biological therapy in rheumatoid arthritis.
Reumatol Clin, 2 (2006), pp. 52-59
[9.]
B. Fautrel, T. Pham, G. Mouterde, X. Le Loet, P. Goupille, F. Guillemin, et al.
Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with rheumatoid arthritis.
Jt Bone Spine, 74 (2007), pp. 627-637
[10.]
S. Jerram, S. Butt, K. Gadsby, C. Deighton.
Discrepancies between the EULAR response criteria and the NICE guidelines for continuation of anti-TNF therapy in RA: a cause for concern?.
Rheumatology (Oxford), 47 (2008), pp. 180-182
[11.]
L. Carmona, J.J. Gomez-Reino.
Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER.
Arthritis Res Ther, 8 (2006), pp. 72
Copyright © 2008. Sociedad Española de Reumatología and Colegio Mexicano de Reumatología
